RayKnowChina Research Map
Shortlist0

RecruitingB-cell acute lymphoblastic leukaemiaPhase 2

Registered title, quoted from ClinicalTrials.gov

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 12 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 12

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Children's Hospital首都医科大学附属北京儿童医院BeijingHospital page
  2. Study siteChildren's Hospital of Chongqing Medical University重庆医科大学附属儿童医院ChongqingHospital page
  3. Study siteChildren's Hospital of Soochow University苏州大学附属儿童医院SuzhouHospital page
  4. Study siteChildren's Hospital, Zhejiang University School of Medicine浙江大学医学院附属儿童医院HangzhouHospital page
  5. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  6. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  7. Study siteInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page
  8. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  9. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  10. Study siteShenzhen Children's Hospital深圳市儿童医院ShenzhenHospital page
  11. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  12. Study siteWest China Second University Hospital四川大学华西第二医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05334823, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 3 years to 21 years; sex: all

    Registered eligibility fields

  2. Refractory B-ALL: early-stage refractory patients who failed to achieve complete remission after 2 courses of standard induction chemotherapy;

    Inclusion criterion 3

  3. Relapsed B-ALL: patients with early relapse (<12 months) after complete remission;or late relapse (≥12 months) after complete remission, and relapsed patients who have not achieved complete remission after standard treatment or have poor response to early treatment; experience Patients with 2 or more bone marrow recurrences; patients with recurrence after allogeneic hematopoietic stem cell transplantation;

    Inclusion criterion 4

    For Ph+ALL patients, patients who have not achieved complete remission after receiving at least two Tyrosine kinase inhibitors (TKI) treatments or have relapsed after complete remission (except those who cannot tolerate TKI treatment or have contraindications to TKI treatment or have T315i mutation resistance to TKI drugs);

    Inclusion criterion 5

    Active central nervous system leukemia at screening, defined as Central Nervous System (CNS)-grade 2 and 3 according to National Comprehensive Cancer Network (NCCN) guidelines (note: those with central nervous system involvement but improved after treatment can be included);

    Exclusion criterion 2

    Received anti-CD19 drug treatment before screening;

    Exclusion criterion 4

    Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy and other drug treatments within 14 days or at least 5 half-lives (whichever is shorter); Received radiotherapy within 14 days;

    Exclusion criterion 5

    Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer;

    Exclusion criterion 16

    Participated in other interventional clinical studies before screening, including: the last use of unmarketed new drugs is less than 3 months from the time of cell reinfusion, or the last use of marketed drugs is less than 5 half-lives from the time of cell reinfusion;

    Exclusion criterion 18

  4. Eastern Cooperative Oncology Group (ECOG) 0-1 points ;

    Inclusion criterion 8

  5. Renal function: serum creatinine≤2.0×ULN;

    Inclusion criterion 12

    Liver function: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤5.0×ULN;

    Inclusion criterion 13

    Total bilirubin≤2.0×ULN (for Gilbert syndrome, total bilirubin≤3.0×ULN);

    Inclusion criterion 14

  6. HBsAg or HBcAb positive and hepatitis B virus (HBV) DNA is greater than the normal range; hepatitis C virus (HCV) antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; Cytomegalovirus (CMV) DNA positive;

    Exclusion criterion 6

  7. Subjects of childbearing age agree to use reliable and effective contraceptive methods for contraception (excluding rhythm contraception) from signing the informed consent to receiving pCAR-19B cell infusion within 1 year.

    Inclusion criterion 18

    Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion;

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05334823, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The patient himself or his guardian agrees to participate in this clinical trial and signs the Informed Consent Form (ICF), indicating that he understands the purpose and procedures of this clinical trial and is willing to participate in the research;
  • Diagnosed with B-ALL,and meet one of the following conditions:
  • Refractory B-ALL: early-stage refractory patients who failed to achieve complete remission after 2 courses of standard induction chemotherapy;
  • Relapsed B-ALL: patients with early relapse (<12 months) after complete remission;or late relapse (≥12 months) after complete remission, and relapsed patients who have not achieved complete remission after standard treatment or have poor response to early treatment; experience Patients with 2 or more bone marrow recurrences; patients with recurrence after allogeneic hematopoietic stem cell transplantation;
  • For Ph+ALL patients, patients who have not achieved complete remission after receiving at least two Tyrosine kinase inhibitors (TKI) treatments or have relapsed after complete remission (except those who cannot tolerate TKI treatment or have contraindications to TKI treatment or have T315i mutation resistance to TKI drugs);
  • The malignant cells in the bone marrow were confirmed to express CD19 by flow cytometry;
  • Bone marrow morphology at the time of screening indicated that blasts≥ 5%;
  • Eastern Cooperative Oncology Group (ECOG) 0-1 points ;
  • Expected survival is ≥ 12 weeks;
  • The function of important organs is basically normal:
  • Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram;
  • Renal function: serum creatinine≤2.0×ULN;
  • Liver function: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤5.0×ULN;
  • Total bilirubin≤2.0×ULN (for Gilbert syndrome, total bilirubin≤3.0×ULN);
  • Blood oxygen saturation≥92% in non-oxygen state.
  • No serious mental disorder;
  • Have apheresis or venous blood collection standards, and have no other contraindications for cell collection;
  • Subjects of childbearing age agree to use reliable and effective contraceptive methods for contraception (excluding rhythm contraception) from signing the informed consent to receiving pCAR-19B cell infusion within 1 year.

Exclusion Criteria:

  • Relapse of isolated extramedullary disease;
  • Active central nervous system leukemia at screening, defined as Central Nervous System (CNS)-grade 2 and 3 according to National Comprehensive Cancer Network (NCCN) guidelines (note: those with central nervous system involvement but improved after treatment can be included);
  • Those who have received CAR-T therapy or other gene-modified cell therapy before screening;
  • Received anti-CD19 drug treatment before screening;
  • Received the following anti-tumor treatments before screening: Received chemotherapy, targeted therapy and other drug treatments within 14 days or at least 5 half-lives (whichever is shorter); Received radiotherapy within 14 days;
  • HBsAg or HBcAb positive and hepatitis B virus (HBV) DNA is greater than the normal range; hepatitis C virus (HCV) antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; Cytomegalovirus (CMV) DNA positive;
  • Have any of the following heart conditions:
  • New York Heart Association (NYHA) stage III or IV congestive heart failure;
  • Myocardial infarction or coronary artery bypass grafting within 6 months prior to enrollment (CABG);
  • Clinically significant ventricular arrhythmia, or history of syncope of unknown origin (by vasovagal except those caused by menstruation or dehydration);
  • History of severe non-ischemic cardiomyopathy;
  • Active infection or uncontrollable infection requiring systemic treatment within 1 week before screening;
  • The presence of grade 2-4 acute graft-versus-host disease (GVHD) or moderate to severe chronic GVHD within 4 weeks before screening;
  • Cerebrovascular accident or epileptic seizure within 6 months before screening;
  • Active autoimmune diseases;
  • Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer;
  • Received live attenuated vaccine within 4 weeks before screening;
  • Participated in other interventional clinical studies before screening, including: the last use of unmarketed new drugs is less than 3 months from the time of cell reinfusion, or the last use of marketed drugs is less than 5 half-lives from the time of cell reinfusion;
  • Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion;
  • Other investigators deem it inappropriate to participate in the study.

Quoted from ClinicalTrials.gov, NCT05334823, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05334823, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05334823